secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nuvalent, Inc. (NUVL)
CIK:        0001861560
Form:       8-K
Filed at:   2024-11-12T23:59:59+00:00
Accession:  0000950170-24-124514
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nuvalent reports Q3 net loss $84.3M; cash $1.2B; pipeline on track for 2025 pivotal data
--------------------------------------------------------------------------------

- Net loss $84.3M for Q3 2024; R&D expenses $60.6M, G&A $15.8M.
- Cash, cash equivalents and marketable securities $1.2B, expected to fund operations into 2028.
- Zidesamtinib (ROS1+) Phase 1 data at ESMO; Phase 2 enrollment ongoing (227 patients), pivotal data expected 2025.
- NVL-655 (ALK+) Phase 2 enrollment ongoing (229 patients); ALKAZAR Phase 3 trial to start H1 2025.
- Appointed Dr. Alice Shaw to Scientific Advisory Board; upsized public offering raised $575M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1861560/000095017024124514/0000950170-24-124514-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1861560/000095017024124514/nuvl-20241112.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-124514

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer